NANOGEN - Ist der Aufstieg vorbei? - 500 Beiträge pro Seite

[panhandler]

Hallo

Wird Nanogen noch steigen, oder wieder auf Tiefstkurs abfallen?

In den nächsten Tagen werden sie ja bekanntlich ihr Ergebnis präsentieren und dabei mit ziemlicher Sicherheit einen noch größeren Verlust bekanntgeben. Weiters wird die Zusammenarbeit mit der US-Regierung ja nicht mehr weitergeführt, da Nanogen nur in der Forschung tätig ist und nicht für die Diagnose, ev. Biochemiegefahren, zuständig ist.

Was denkt ihr? Hofft ihr weiterhin mit mir, oder werdet ihr verkaufen?

Tschau

[nobes]

Ich bin letzte Woche bei 9,5 raus.
30 % mitgenommen, auch nicht schlecht.

[tst89]

@all

Ich bleibe auf jeden Fall dabei! Falls der Kzurs wieder ein
wenig nachgibt (was ich nicht glaube!) werde ich auf
jeden Fall nachkaufen....

Sehr es so.....lieber konstant immer wieder einige 10% mit einer
guten Firma als einmal 100% hoch und den Verkauf verpasst
wo sich die Story der Firma als Luftblase entpuppt hat.

Ich bleibe bei einer Firma wie Nanogen.
Da weiß man was man hat!

tst

[Maxxtro]

Morgen zusammen..

Hier die neuesten News.

Nanogen to Host Webcast; Company to Outline the Development Path of Molecular Diagnostics
TUESDAY, OCTOBER 30, 2001 9:55 PM
- PRNewswire

Nanogen to Host Webcast; Company to Outline the Development Path of Molecular Diagnostics

SAN DIEGO, Oct 30, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc. will host a webcast on Tuesday, November 6, 2001 at 12:15 p.m. Eastern Time. Management will discuss the development path of molecular diagnostics as it relates to the genomics industry.

The audio and slide presentation will be available live via webcast on the investor relations section of Nanogen`s corporate website at . The presentation will be archived on the Company`s website.

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical settings. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and validated research protocols for the detection of the Factor II and Factor V Leiden gene mutations and a multiplexed format Factor II/Factor V gene mutation combination, all associated with cardiovascular disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at .

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.


SOURCE Nanogen, Inc.


Copyright (C) 2001 PR Newswire. All rights reserved.

MfG..

[swoasik]

Hallo"Nanogenler"
Hoffe die Zahlen fallen gut aus???
Habe aber trozdem einen Stop bei 7,65 gesetzt.Werde aber der
Aktie treu bleiben,um evtl,wieder billiger einsteigen.
Wie seht ihr das? Da ich zugeben muß,nicht besonders viel Informationen zu haben.Was aber nicht an diesen wirklich guten Bord liegt, sondern mehr an der wenigen Zeit die ich
habe.
Danke Swoasik@

[xxxyyy]

Wann kommen die Q-Zahlen von Nanogen?

Gruß xxxyyy

[panhandler]

Die Quartalszahlen kommen heute.

Hier mal ein Link, auf dem es die neuesten Nanogennews gibt.

http://www.hoovers.com/co/news/1/0,2171,55551,00.html

[matthiasch]

Hoffe für euch, dass es keine Halloween-Zahlen werden!

[herbertraubvogel]

Die Zahlen sind da.Schlechte.

HRV

[herbertraubvogel]

Die Zahlen sind da.Schlechte.

HRV

[Brucky]

Und?Hat einer en Tip wie die Zahlen waren?
Danke
Brucky

[panhandler]

Quatsch. Wer schreibt hier was von schlechten Zahlen. Natürlich Verlust, wie alle Biotechunternehmen, aber weniger als erwartet und außerdem bekommen sie von der US-REgierung für mind. 3 Jahre Unterstützung. So schlecht waren die Zahlen nicht. Kurs steigt jedenfalls.

[Brucky]

Die Zahlen waren wohl doch nicht so gut.Vorbörslich -5,5%.Aber was solls!Ist ja nur Geld.
Gruss
Brucky

[_vanessa_]

vollständigkeitshalber hier der quartalsbericht, für jene wie mich, die nicht in nanogen investiert sind und daher nicht immer auf dem laufenden sind, sich trotzdem dafür interessieren.


Nanogen Reports 2001 Third Quarter Results;

October 31, 2001 4:00pm


Achieves Record Product Revenues for Quarter

SAN DIEGO, Oct. 31 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the third quarter ended September 30, 2001.

Product revenues for the third quarter of 2001 were $1.0 million, an increase of 88% over the third quarter last year and more than three times the second quarter of 2001. During the current quarter, Nanogen sold seven NanoChip® Molecular Biology Workstations and additionally entered into three non-title transfer transactions under new Development Site Agreements. Total revenues for the quarter ended September 30, 2001 were $3.2 million compared to $3.5 million for the same period in 2000. The decline in total revenues was due to an anticipated decrease in revenues earned in connection with sponsored research programs as the Company`s revenue base transitions from primarily sponsored research revenues to product revenues.



For the first nine months of 2001, product revenues were $1.6 million, as compared to $709,000 for the first nine months of last year. For the first nine months of 2001, total revenues were $8.9 million as compared to $8.2 million for the same period in 2000. Revenue recognized during the nine months ended September 30, 2001 was primarily earned under sponsored research programs from the Company`s corporate alliances and from contracts or grants with government agencies.

The Company`s cash, cash equivalents and short-term investment balance at September 30, 2001 was $75.1 million. Total operating expenses for the third quarter of 2001 were $11.9 million, as compared to $9.9 million for the same period in 2000. For the first nine months of 2001, total operating expenses, excluding charges totaling $6.4 million related to the defense and settlement of a patent litigation matter, were $31.5 million compared to $24.3 million for the same period in 2000. The increases in operating expenses for both the third quarter of 2001 and for the first nine months of 2001, as compared to the same periods in 2000, were primarily due to increased sales and marketing expenses as the Company expanded its sales and marketing organization.

The reported net loss for the quarter ended September 30, 2001 was

$7.0 million, or $0.33 per share compared to a net loss of $4.6 million, or $0.22 per share for the same period in 2000. For the first nine months of 2001, inclusive of the defense and settlement charges noted above of
$6.4 million, the Company reported a net loss of $25.0 million or $1.20 per share. For the nine months ended September 30, 2001, excluding the defense and settlement charges noted above of $6.4 million, the Company reported a net loss of $18.6 million or $0.89 per share, compared to a net loss of
$12.4 million or $0.62 per share for the same period in 2000.

Highlights for the third quarter ended September 30, 2001 include:

-- The development and internal validation of the Company`s first

DNA-based research protocol, for Factor V Leiden, a mutation associated

with cardiovascular disease and the research pathology of thrombosis,

for use on the NanoChip® Molecular Biology Workstation.

Additionally, since the end of the quarter, the Company has also

announced the internal validation for two additional research

protocols. The first was for Factor II (Prothrombin), also a key

marker in the detection and risk assessment of certain cardiovascular

disorders, and the second was for a multiplexed format

Factor II/Factor V gene mutation combination at a single location on

the NanoChip® electronic microarray.

-- The resolution of the Company`s litigation with Motorola, Genometrix

and MIT by securing a license from Motorola to certain claims of U.S.

Patent No. 5,653,939 entitled "Optical and Electrical Methods and

Apparatus for Molecular Detection." This provides Nanogen the freedom

to operate under these claims, which relate to electronic

hybridization. Nanogen resolved the litigation without providing

access to Nanogen`s own technology and on favorable terms. To its

knowledge, Nanogen remains the only current provider of commercially

available electronic-aided hybridization products.

-- The awarding of an additional five United States patents broadening the

Company`s already strong patent portfolio and bringing the Company`s

total number of issued patents as of October 31, 2001 to 35 in the

United States and 21 abroad. The patents awarded to the Company since

the end of the third quarter include two additional patents relating to

the Company`s permeation layer technology.

Additionally, Nanogen recently announced that it had been awarded a three-year, $1.5 million grant from the U.S. Army to develop a miniaturized electronic device for isolating and detecting biological warfare and infectious disease agents from human blood samples.

"We are delighted to have had a record quarter for product revenues. The initiatives we have taken to accelerate our planned entry into the clinical diagnostics market are achieving their desired results," said Howard C. Birndorf, Executive Chairman and Co-Founder of Nanogen. "The organization is delivering on our commitment to expand the NanoChip® System`s menu, a critical indicator of the system`s flexibility and market appropriateness."

Webcast of Conference

Nanogen management will hold a conference call to discuss third quarter financial results today at 4:30 p.m. Eastern Time. A live webcast is available via Nanogen`s website at http://www.nanogen.com A telephone replay of the conference call also will be available for 48 hours at 800-428-6051 (domestic) or 973-709-2089 (international), passcode ID #214039. The webcast will be available on Nanogen`s website through November 14, 2001.

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical settings. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and validated research protocols for the detection of the Factor II and Factor V Leiden gene mutations and a multiplexed format Factor II/Factor V gene mutation combination, all associated with cardiovascular disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

NANOGEN, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

September 30, December 31,

2001 2000

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents $14,249 $55,330

Short-term investments 60,816 39,759

Accounts receivable 3,581 1,322

Inventory 4,212 2,289

Other current assets 2,534 1,689

Total current assets 85,392 100,389

Property and equipment, net 5,556 5,373

Acquired technology rights, net 4,339 5,179

Other assets 1,286 63

Restricted cash 114 164

$96,687 $111,168

LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:

Accounts payable $943 $1,223

Accrued liabilities 3,730 4,095

Deferred revenue 681 360

Current portion of capital lease obligations 1,191 2,011

Total current liabilities 6,545 7,689

Capital lease obligations, less current portion 1,720 1,565

Other long-term liabilities 1,669 500

Total long-term liabilities 3,389 2,065

Minority interest in consolidated subsidiary 4,800 --

Stockholders` equity:

Convertible preferred stock, $.001 par

value, 5,000,000 shares authorized;

no shares issued and outstanding at

September 30, 2001 and December 31, 2000 -- --

Common stock, $.001 par value,

50,000,000 shares authorized; 21,435,211

and 20,913,151 shares issued and

outstanding at September 30, 2001 and

December 31, 2000, respectively 21 21

Additional paid-in capital 197,630 193,459

Accumulated other comprehensive income 1,432 270

Deferred compensation (199) (325)

Notes receivable from officers (970) (1,099)

Accumulated deficit (115,961) (90,912)

Total stockholders` equity 81,953 101,414

$96,687 $111,168

NANOGEN, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

Three months ended Nine months ended

September 30, September 30,

2001 2000 2001 2000

Revenues:

Sales $1,023 $545 $1,554 $709

Sponsored research 1,828 2,565 6,229 6,132

Contract and grant revenue 368 436 1,091 1,370

Total revenues 3,219 3,546 8,874 8,211

Operating expenses:

Cost of sales 727 437 1,127 450

Research and development 4,824 5,445 14,023 14,202

Selling, general

and administrative 6,194 4,026 16,386 9,651

Litigation and settlement

of patent matter 123 -- 6,432 --

Total operating expenses 11,868 9,908 37,968 24,303

Loss from operations (8,649) (6,362) (29,094) (16,092)

Interest income, net 1,019 1,783 3,437 3,722

Minority interest in loss

of consolidated subsidiary 485 -- 485 --

Gain on sale of investments 116 -- 116 --

Gain on foreign currency

transactions 9 -- 7 --

Net loss $ (7,020) $ (4,579) $ (25,049) $ (12,370)

Net loss per share -

basic and diluted $(0.33) $(0.22) $(1.20) $(0.62)

Number of shares used in

computing net loss per

share - basic and diluted 21,206 20,360 20,898 19,797